03 May 2016
AstraZeneca is an innovation-driven, global biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. It operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. The company has recently announced that it has completed the acquisition of Takeda Pharmaceutical Company Limited’s core respiratory business.
The agreement was announced in December 2015, which includes the expansion of rights to roflumilast (marketed in the US as Daliresp and Daxas in other countries). This is the only approved oral PDE4 inhibitor for treating chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.AstraZeneca Acquires Takeda’s respiratory businesslast edit: 2016-05-11T18:00:41+00:00da